Cargando…
Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer
OBJECTIVE: To compare Prostate Health Index (PHI) and prostate‐specific antigen (PSA) density as secondary tests after multiparametric magnetic resonance imaging (mpMRI) in improving the detection accuracy of Gleason grade group (GG) 2‐5 prostate cancer (PCa) and in decreasing unnecessary biopsies i...
Autores principales: | Carbunaru, Samuel, Stinson, James, Babajide, Rilwan, Hollowell, Courtney M. P., Yang, Ximing, Sekosan, Marin, Ferrer, Karen, Kajdacsy‐Balla, Andre, Abelleira, Josephine, Ruden, Maria, King‐Lee, Patrice, Dalton, Daniel P., Casalino, David D., Kittles, Rick A., Gann, Peter H., Schaeffer, Edward M., Murphy, Adam B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988695/ https://www.ncbi.nlm.nih.gov/pubmed/35474697 http://dx.doi.org/10.1002/bco2.91 |
Ejemplares similares
-
Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017) -
Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023) -
Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022) -
Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?
por: Rezaee, Michael E., et al.
Publicado: (2020) -
The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
por: Zhang, Xin, et al.
Publicado: (2022)